Sonophore labeled RGD: a targeted contrast agent for optoacoustic imaging

Photoacoustics

Vasilis Ntziachristos¹  Murad Omar¹  Thomas Reiner²  Christian Brand²  Jan Grimm³  Katja Haedicke³ 

[1] Chair of Biological Imaging, Technische Universitaet Muenchen, Munich, Germany;Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

关键词: Optoacoustic imaging;    Photoacoustic imaging;    Black hole quencher;    RGD peptide;    Contrast agent;    Sonophore;   

DOI  :  10.1016/j.pacs.2017.03.001

来源: DOAJ

【 摘 要 】

Optoacoustic imaging is a rapidly expanding field for the diagnosis, characterization, and treatment evaluation of cancer. However, the availability of tumor specific exogenous contrast agents is still limited. Here, we report on a small targeted contrast agent for optoacoustic imaging using a black hole quencher® (BHQ) dye. The sonophore BHQ-1 exhibited strong, concentration-dependent, optoacoustic signals in phantoms, demonstrating its ideal suitability for optoacoustic imaging. After labeling BHQ-1 with cyclic RGD-peptide, BHQ-1-cRGD specifically bound to αvβ3-integrin expressing glioblastoma cell spheroids in vitro. The excellent optoacoustic properties of BHQ-1-cRGD could furthermore be proven in vivo. Together with this emerging imaging modality, our sonophore labeled small peptide probe offers new possibilities for non-invasive detection of molecular structures with high resolution in vivo and furthers the specificity of optoacoustic imaging. Ultimately, the discovery of tailor-made sonophores might offer new avenues for various molecular optoacoustic imaging applications, similar to what we see with fluorescence imaging.

【 授权许可】

Unknown